TP53 and cancer: Even without therapeutic success, the developed mAbs will offer extraordinary values in cancer companion or complementary diagnostics (e.g., to detect mutant p53 protein levels for therapeutics based on T-cell receptors48, 49, 50, 51 or small compound inhibitors53, 54, 55, 56).